|View printer-friendly version|
|La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock|
Cowen is acting as the sole book-running manager for the offering.
La Jolla intends to use the proceeds from the proposed sale of its shares of common stock for general corporate purposes, which include, but are not limited to, the continued commercialization of GIAPREZA™ (angiotensin II), funding its ongoing and future clinical trials of LJPC-401, preclinical development work and other administrative expenses.
The offering is expected to close on or about
The offering is being made pursuant to a registration statement that was filed with the
|Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts|